About this item:

83 Views | 77 Downloads

Author Notes:

Elliot L. Chaikof, 110 Francis St, Suite 9F, Boston, MA 02215, USA. Tel.: +1 617 632 9581. echaikof@bidmc.harvard.edu

Subjects:

Research Funding:

This project was funded by a grant from the Boston Scientific Corporation.

Keywords:

  • Science & Technology
  • Technology
  • Engineering, Biomedical
  • Materials Science, Biomaterials
  • Engineering
  • Materials Science
  • Bone marrow
  • Growth factors
  • ECM (extracellular matrix)
  • Heart
  • Thermally responsive material
  • Porcine tissue
  • FIBROBLAST-GROWTH-FACTOR
  • SMALL-INTESTINAL SUBMUCOSA
  • MYOCARDIAL INFARCT REPAIR
  • PROGENITOR CELLS
  • TRANSFORMING GROWTH-FACTOR-BETA-1
  • ANGIOGENIC CYTOKINES
  • VENTRICULAR-FUNCTION
  • PEPTIDE NANOFIBERS
  • IN-VITRO
  • PDGF-BB

Effect of bone marrow-derived extracellular matrix on cardiac function after ischemic injury

Tools:

Journal Title:

Biomaterials

Volume:

Volume 33, Number 31

Publisher:

, Pages 7736-7745

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Ischemic heart disease is a leading cause of death, with few options to retain ventricular function following myocardial infarction. Hematopoietic-derived progenitor cells contribute to angiogenesis and tissue repair following ischemia reperfusion injury. Motivated by the role of bone marrow extracellular matrix (BM-ECM) in supporting the proliferation and regulation of these cell populations, we investigated BM-ECM injection in myocardial repair. In BM-ECM isolated from porcine sternum, we identified several factors important for myocardial healing, including vascular endothelial growth factor, basic fibroblast growth factor-2, and platelet-derived growth factor-BB. We further determined that BM-ECM serves as an adhesive substrate for endothelial cell proliferation. Bone marrow ECM was injected in a rat model of myocardial infarction, with and without a methylcellulose carrier gel. After one day, reduced infarct area was noted in rats receiving BM-ECM injection. After seven days we observed improved fractional shortening, decreased apoptosis, and significantly lower macrophage counts in the infarct border. Improvements in fractional shortening, sustained through 21 days, as well as decreased fibrotic area, enhanced angiogenesis, and greater c-kit-positive cell presence were associated with BM-ECM injection. Notably, the concentrations of BM-ECM growth factors were 10 3 -10 8 fold lower than typically required to achieve a beneficial effect, as reported in pre-clinical studies that have administered single growth factors alone.

Copyright information:

© 2012 Elsevier Ltd.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote